Ray Stevens, CEO of Structure Therapeutics, joins 'Squawk on the Street' to discuss the company's weight loss pill, ...
Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety ...
Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an ...
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug ...
In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...
By Puyaan Singh and Sahil Pandey March 16 (Reuters) - Structure Therapeutics said on Monday its pill helped patients lose up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results